Paul Hastings advised TD Cowen and Wedbush PacGrow, as joint book-running managers, in connection with Monte Rosa Therapeutics’ (Nasdaq: GLUE) underwritten public offering. The offering is expected to close on May 20, 2024, subject to satisfaction of customary closing conditions.

More details on the transaction can be found here.

Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi led the Paul Hastings team, which also included Securities and Capital Markets partner Will Magioncalda; and associates Chris Guerin and Adam Swank.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.